Eribulin mesylate (purity>99%, single impurity ≤ 0.15%)
Based on 3 publication(s) in Google Scholar
Eribulin (B1939; E7389; ER-086526) mesylate (purity>99%, single impurity ≤ 0.15%) is an inhibitor for microtubule. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) inhibits the proliferation of cancer cell LM8 and Dunn, inhibits the cell migration of LM8, arrests the cell cycle at G2/M phase, and induces apoptosis in LM8. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) exhibits antitumor efficacy in mouse model.
For research use only. We do not sell to patients.
- CAS No.: 441045-17-6
- Formula: C41H63NO14S
- Molecular Weight:826.00
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Eribulin mesylate (purity>99%, single impurity ≤ 0.15%)
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MES-SA | IC50 |
1.66 nM
Compound: Halaven
|
Antiproliferative activity against human MES-SA cells
Antiproliferative activity against human MES-SA cells
|
[PMID: 21324687] |
| MES-SA | IC50 |
1.7 nM
Compound: 1
|
Cytotoxicity against human MES-SA cells
Cytotoxicity against human MES-SA cells
|
[PMID: 23141916] |
| SF-295 | IC50 |
27.85 nM
Compound: Halaven
|
Antiproliferative activity against human SF295 cells
Antiproliferative activity against human SF295 cells
|
[PMID: 21324687] |
| U-251 | IC50 |
5.87 nM
Compound: Halaven
|
Antiproliferative activity against human U251 cells
Antiproliferative activity against human U251 cells
|
[PMID: 21324687] |
In Vitro
Eribulin mesylate (1-100 nM; 72 h) (purity>99%, single impurity ≤ 0.15%) inhibits cells proliferation, with IC50s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively[1].
Eribulin mesylate (10-50 nM; 12-72 h) (purity>99%, single impurity ≤ 0.15%) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells[1].
Eribulin mesylate (10-50 nM; 12-72 h) (purity>99%, single impurity ≤ 0.15%) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells[1].
Eribulin mesylate (1-50 nM; 12 h) (purity>99%, single impurity ≤ 0.15%) does not induce senescence in LM8 cells[1].
Eribulin mesylate (1-10 nM; 16 h) (purity>99%, single impurity ≤ 0.15%) induces morphological change and suppresses cell migration in a low concentration in LM8 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LM8 cells and Dunn cells
-
Concentration:0, 1, 10, 100 nM
-
Incubation Time:72 hours
-
Result:Inhibited cells proliferation in a dose-dependent manner.
-
Cell Line:LM8 cells
-
Concentration:0, 10, 50 nM
-
Incubation Time:12, 24, 48, 72 hour
-
Result:Induced early apoptosis after 12 h at the concentration of 50 nM.
Not detected apoptosis at the concentration of 10 nM.
-
Cell Line:LM8 cells
-
Concentration:0, 10, 50 nM
-
Incubation Time:12, 24, 48, 72 hour
-
Result:Induced G2/M arrest by 12 h treatment with 50 nM.
No G2/M arrest was induced by10 nM treatment.
In Vivo
Eribulin mesylate (1 mg/kg; once i.v.) (purity>99%, single impurity ≤ 0.15%) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C3H/HeN mice (4-week-old) are injected LM8 cells[1] 1 mg/kg I.v. once a week for 2 weeks Suppressed primary tumor growth and induced apoptosis in tumor cells.
Reduced lung metastasis.
-
Dosage:1 mg/kg
-
Administration:I.v. once a week for 2 weeks
-
Result:Suppressed primary tumor growth and induced apoptosis in tumor cells.
Reduced lung metastasis.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 441045-17-6
-
Molecular Weight 826.00
-
Formula C41H63NO14S
-
SMILES
C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O.CS(=O)(O)=O
-
Synonyms
B1939 mesylate (purity>99%, single impurity ≤ 0.15%); E7389 mesylate (purity>99%, single impurity ≤ 0.15%); ER-086526 mesylate (purity>99%, single impurity ≤ 0.15%)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
mBio
2025 Aug 15:e0048425. PMID: 40815147 -
Molecules
Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1 (APC1) Potentiate Paclitaxel-Induced Breast Cancer Cell Death. [Abstract]2025 Feb 14;30(4):895. PMID: 40005207
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) Related Classifications
HY-13442C Related Classifications
Powered by Bioz